These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23247772)

  • 1. A proposal for a simplified MASCC score.
    Wierema JC; Links M
    Support Care Cancer; 2013 Apr; 21(4):915-6. PubMed ID: 23247772
    [No Abstract]   [Full Text] [Related]  

  • 2. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
    Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
    Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study].
    Cervetti L; Vallard A; Le Moulec S; Espenel S; Falk AT; Ben Mrad M; Guy JB; Diao P; Méry B; Langrand-Escure J; Ferrand FR; Rivoirard R; Ceccaldi B; Védrine L; Magné N; Chargari C
    Bull Cancer; 2016 Jun; 103(6):561-70. PubMed ID: 27181759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.
    Gunderson CC; Erickson BK; Wilkinson-Ryan I; Vesely SK; Leath CA; Gehrig PA; Moore KN
    Am J Clin Oncol; 2019 Feb; 42(2):138-142. PubMed ID: 30557164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful?
    Gunderson CC; Farrell R; Dinh BC; Thomas ED; Vesely SK; Lauer JK; Kao L; Chopra S; McMeekin DS; Moore KN
    Gynecol Oncol; 2013 Sep; 130(3):411-5. PubMed ID: 23791827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?
    Paesmans M; Klastersky J; Maertens J; Georgala A; Muanza F; Aoun M; Ferrant A; Rapoport B; Rolston K; Ameye L
    Support Care Cancer; 2011 Jul; 19(7):1001-8. PubMed ID: 20596732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The time has come for new models in febrile neutropenia: a practical demonstration of the inadequacy of the MASCC score.
    Carmona-Bayonas A; Jiménez-Fonseca P; Virizuela Echaburu J; Sánchez Cánovas M; Ayala de la Peña F
    Clin Transl Oncol; 2017 Sep; 19(9):1084-1090. PubMed ID: 28289961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
    Hui EP; Leung LK; Poon TC; Mo F; Chan VT; Ma AT; Poon A; Hui EK; Mak SS; Lai M; Lei KI; Ma BB; Mok TS; Yeo W; Zee BC; Chan AT
    Support Care Cancer; 2011 Oct; 19(10):1625-35. PubMed ID: 20820815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
    de Souza Viana L; Serufo JC; da Costa Rocha MO; Costa RN; Duarte RC
    Support Care Cancer; 2008 Jul; 16(7):841-6. PubMed ID: 17960431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
    Mohindra R; Mathew R; Yadav S; Aggarwal P
    Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
    Cherif H; Johansson E; Björkholm M; Kalin M
    Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia.
    Taj M; Nadeem M; Maqsood S; Shah T; Farzana T; Shamsi TS
    Indian J Hematol Blood Transfus; 2017 Sep; 33(3):355-360. PubMed ID: 28824237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of anxiety and depression in palliative care patients with cancer in Western Australia and New South Wales.
    O'Connor M; White K; Kristjanson LJ; Cousins K; Wilkes L
    Med J Aust; 2010 Sep; 193(S5):S44-7. PubMed ID: 21542445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.
    Ahn S; Lee YS; Chun YH; Kwon IH; Kim W; Lim KS; Kim TW; Lee KH
    Support Care Cancer; 2011 Aug; 19(8):1151-8. PubMed ID: 20552376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
    Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
    Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.